CytRx Rating Reiterated by Aegis (CYTR)
CytRx (NASDAQ:CYTR)‘s stock had its “buy” rating restated by research analysts at Aegis in a report released on Monday, StockRatingsNetwork reports.
Shares of CytRx (NASDAQ:CYTR) traded down 0.30% on Monday, hitting $3.37. 427,181 shares of the company’s stock traded hands. CytRx has a one year low of $1.59 and a one year high of $3.73. The stock has a 50-day moving average of $2.4 and a 200-day moving average of $2.. The company’s market cap is $102.7 million.
CytRx (NASDAQ:CYTR) last announced its earnings results on Tuesday, August 6th. The company reported ($0.11) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.19) by $0.08. On average, analysts predict that CytRx will post $-0.76 earnings per share for the current fiscal year.
Separately, analysts at Zacks downgraded shares of CytRx (NASDAQ:CYTR) to a “neutral” rating in a research note to investors on Thursday, July 4th. They now have a $2.30 price target on the stock.
CytRx Corporation as (NASDAQ:CYTR) is a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, specializing in oncology.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.